Researched by Belong.Life and published by ASCO
Data from the Belong PPN successfully captured the spectrum of PD-1 inhibitors’ reported AEs. Analyzing PRO of post approval treatments could provide deeper understanding of treatment patterns, expose limiting AE that bear implications on cost of treatment, indicate patients’ quality of life (QOL), improve management recommendations and provide a comprehensive outlook of patients’ outcomes.
Belong.Life is a leading global tech provider of high-engagement patient communities and care platforms, supporting millions of patients worldwide.
Among Belong.Life’s brands are the world’s largest social and professional networks for cancer patients (Belong – Beating Cancer Together) and multiple sclerosis patients (BelongMS), as well as i-Belong, BelongIBD, BelongPSO, CoronApp (in selected countries), and more.
Belong.Life’s mission is to improve quality of life and quality of care worldwide through technology, engagement, data, and AI.
